HIPEC in combined treatment of intraperitoneally disseminated cancer: a monocentric experience of 215 operations
Yarema R.R. 1, Fetsych Т.G.1, Ohorchak М.А.2, Volodko N.A. 1, Gyrya P.I. 2, Kovalchuk Y.Y.2, Safiyan V.I. 2, Mylyan Y.P. 2, Matusyak M.B. 2, Oliynyk Y.Y.1, Novitska T.I.2, Laba L.I.2, Yarysh M.I.2, Fetsych M.T.1, Ferneza S.R.1
- 1Danylo Halytsky Lviv National Medical University
- 2Lviv State Oncological Regional Treatment and Diagnostic Center
Summary. Introduction. In the traditional modern discourse of conservative palliative treatment of disseminated cancer over the past two decades, methods of active combined treatment of such patients have become increasingly common. The method of hyperthermic intraperitoneal chemotherapy (HIPEC) is widely used today for patients with peritoneal metastases of various genesis, Aim. Retrospective analysis of clinical efficacy of combined therapy using HIPEC in patients with intraperitoneally disseminated cancer of different localizations and determination of prognostic factors for such patients. Materials and methods. The results of a 12-year period of HIPEC use in the combined treatment of patients with locally advanced and disseminated gastric cancer, primary and recurrent ovarian cancer, colorectal cancer, peritoneal pseudomyxoma, peritoneal sarcomatosis, etc. were analyzed. 215 HIPEC procedures were performed for 211 patients. The prognostic factors and further perspective directions of development of combined treatment of such patients are determined. Conclusion. Combined therapy with HIPEC is a safe method with acceptable levels of postoperative morbidity and mortality. The use of active combined therapy tactics ensures long survival in selected patients with intraperitoneally disseminated cancer.
Leave a comment